Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | SFRP1 | Q8N474 | 8/20 | 0.43 |
| ▸ | WNT3 | P56703 | 3/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14997376 | 1.00 | DRD2 (0.46) | DRD2ADRA1DADRA1AADRA1BCACNA1B | |
| SCHEMBL4286631 | 0.86 | CACNA1B (0.56) | CACNA1BNR1I2 | |
| SCHEMBL8268668 | 0.85 | CACNA1B (0.46) | DRD2ADRA1DADRA1AADRA1BCACNA1B | |
| SCHEMBL13880081 | 0.85 | CACNA1B (0.47) | DRD2ADRA1DADRA1AADRA1BCACNA1B | |
| SCHEMBL8268664 | 0.81 | CACNA1B (0.53) | DRD2ADRA1DADRA1AADRA1BCACNA1B | |
| SCHEMBL4281416 | 0.80 | STS (0.60) | DRD2ADRA1DADRA1AADRA1BTGFBR1 | |
| SCHEMBL5503404 | 0.80 | SFRP1 (0.45) | DRD2ADRA1DADRA1AADRA1BCACNA1B | |
| Fumaric Acid SCHEMBL4287224 | 0.76 | CACNA1B (0.49) | DRD2ADRA1DADRA1AADRA1BCACNA1B | |
| Fumaric Acid SCHEMBL4287220 | 0.76 | CACNA1B (0.49) | DRD2ADRA1DADRA1AADRA1BCACNA1B | |
| SCHEMBL16497731 | 0.74 | CACNA1B (0.80) | CACNA1BGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000174-B2 | 4-phenylsulfonamidopiperidines as calcium channel blockers | PURDUE PHARMA L.P. (US) | 2015-04-07 | — | — | US | disclosed |
| EP-1814851-B1 | 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS | EURO CELTIQUE SA (LU) | 2013-06-05 | — | — | EP | disclosed |
| US-20090105249-A1 | 4-phenylsulfonamidopiperidines as calcium channel blockers | EURO-CELTIQUE S.A. (LU) | 2009-04-23 | — | — | US | disclosed |
| EP-1814851-A2 | 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006040181-A2 | 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105249-A1 | 4-phenylsulfonamidopiperidines as calcium channel blockers | CACNA1A, CACNA1E, CACNA1B | DRD2 347/4885ADRA1D 263/4885ADRA1A 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.